Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Cottu

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
The Oncologist|May 7, 2026
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancerAdam Brufsky, Rachel M Layman, Xianchen Liu, et al.
Frontiers in Oncology|October 5, 2020
Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an Independent Risk Factor for Inpatient Mortality in a Population of Cancer Patients: A Prospective StudyToulsie Ramtohul, Luc Cabel, Xavier Paoletti, et al.
British Journal of Cancer|December 15, 2015
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Oncotarget|October 2, 2015
First description of a sporadic breast cancer in a woman with BRCA1 germline mutationElsa Curtit, Vanessa Benhamo, Nadège Gruel, et al.
British Journal of Cancer|February 21, 2018
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Nature Medicine|November 22, 2011
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress responseBogdan Mateescu, Luciana Batista, Melissa Cardon, et al.
Journal of Pain and Symptom Management|August 3, 2020
A Question Prompt List for Advanced Cancer Patients Promoting Advance Care Planning: A French Randomized TrialCarole Bouleuc, Alexia Savignoni, Marion Chevrier, et al.
The Breast Journal|May 31, 2017
Pattern of relapse in low-risk breast cancer patients followed within a community care networkAnahid Agopian, Coraline Dubot, Sophie Houzard, et al.
World Journal of Radiology|August 18, 2012
Concurrent use of aromatase inhibitors and hypofractionated radiation therapyCyrus Chargari, Pablo Castro-Pena, Ivan Toledano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 31, 2007
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal womenMarc A Bollet, Youlia M Kirova, Guillemette Antoni, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
The Oncologist|May 7, 2026
Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancerAdam Brufsky, Rachel M Layman, Xianchen Liu, et al.
Frontiers in Oncology|October 5, 2020
Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an Independent Risk Factor for Inpatient Mortality in a Population of Cancer Patients: A Prospective StudyToulsie Ramtohul, Luc Cabel, Xavier Paoletti, et al.
British Journal of Cancer|December 15, 2015
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Oncotarget|October 2, 2015
First description of a sporadic breast cancer in a woman with BRCA1 germline mutationElsa Curtit, Vanessa Benhamo, Nadège Gruel, et al.
British Journal of Cancer|February 21, 2018
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Nature Medicine|November 22, 2011
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress responseBogdan Mateescu, Luciana Batista, Melissa Cardon, et al.
Journal of Pain and Symptom Management|August 3, 2020
A Question Prompt List for Advanced Cancer Patients Promoting Advance Care Planning: A French Randomized TrialCarole Bouleuc, Alexia Savignoni, Marion Chevrier, et al.
The Breast Journal|May 31, 2017
Pattern of relapse in low-risk breast cancer patients followed within a community care networkAnahid Agopian, Coraline Dubot, Sophie Houzard, et al.
World Journal of Radiology|August 18, 2012
Concurrent use of aromatase inhibitors and hypofractionated radiation therapyCyrus Chargari, Pablo Castro-Pena, Ivan Toledano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 31, 2007
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal womenMarc A Bollet, Youlia M Kirova, Guillemette Antoni, et al.
Pageof 14